vs

Side-by-side financial comparison of INTERGROUP CORP (INTG) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.

INTERGROUP CORP is the larger business by last-quarter revenue ($17.3M vs $13.7M, roughly 1.3× Xilio Therapeutics, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs 8.8%, a 66.9% gap on every dollar of revenue. INTERGROUP CORP produced more free cash flow last quarter ($-481.0K vs $-2.1M).

Intergroup Corp is a diversified holding firm operating two core segments: real estate and hotel operations. It owns, manages and leases commercial and residential properties across the U.S., and runs limited-service hotels for leisure and business travelers.

Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.

INTG vs XLO — Head-to-Head

Bigger by revenue
INTG
INTG
1.3× larger
INTG
$17.3M
$13.7M
XLO
Higher net margin
XLO
XLO
66.9% more per $
XLO
75.7%
8.8%
INTG
More free cash flow
INTG
INTG
$1.6M more FCF
INTG
$-481.0K
$-2.1M
XLO

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
INTG
INTG
XLO
XLO
Revenue
$17.3M
$13.7M
Net Profit
$1.5M
$10.4M
Gross Margin
Operating Margin
11.6%
-86.5%
Net Margin
8.8%
75.7%
Revenue YoY
19.8%
Net Profit YoY
155.6%
179.1%
EPS (diluted)
$0.71
$-3.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INTG
INTG
XLO
XLO
Q4 25
$17.3M
$13.7M
Q3 25
$17.9M
$19.1M
Q2 25
$16.2M
$8.1M
Q1 25
$16.8M
$2.9M
Q4 24
$14.4M
Q3 24
$16.9M
Q2 24
$13.4M
Q1 24
$14.9M
Net Profit
INTG
INTG
XLO
XLO
Q4 25
$1.5M
$10.4M
Q3 25
$-535.0K
$-16.3M
Q2 25
$-2.2M
$-15.8M
Q1 25
$-578.0K
$-13.3M
Q4 24
$-2.7M
Q3 24
$-398.0K
Q2 24
$-4.9M
Q1 24
$-3.2M
Operating Margin
INTG
INTG
XLO
XLO
Q4 25
11.6%
-86.5%
Q3 25
15.3%
-10.1%
Q2 25
8.1%
-177.7%
Q1 25
14.0%
-472.7%
Q4 24
5.9%
Q3 24
18.5%
Q2 24
3.7%
Q1 24
4.8%
Net Margin
INTG
INTG
XLO
XLO
Q4 25
8.8%
75.7%
Q3 25
-3.0%
-85.4%
Q2 25
-13.9%
-196.0%
Q1 25
-3.4%
-452.7%
Q4 24
-18.9%
Q3 24
-2.4%
Q2 24
-36.7%
Q1 24
-21.3%
EPS (diluted)
INTG
INTG
XLO
XLO
Q4 25
$0.71
$-3.74
Q3 25
$-0.25
$-0.11
Q2 25
$-0.16
Q1 25
$-0.27
$-0.18
Q4 24
$-1.26
Q3 24
$-0.18
Q2 24
Q1 24
$-1.44

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INTG
INTG
XLO
XLO
Cash + ST InvestmentsLiquidity on hand
$7.5M
$137.5M
Total DebtLower is stronger
$233.2M
Stockholders' EquityBook value
$-85.2M
$35.3M
Total Assets
$101.1M
$154.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INTG
INTG
XLO
XLO
Q4 25
$7.5M
$137.5M
Q3 25
$6.0M
$103.8M
Q2 25
$6.1M
$121.6M
Q1 25
$4.8M
$89.1M
Q4 24
$15.4M
Q3 24
$12.2M
Q2 24
$11.6M
Q1 24
$19.5M
Total Debt
INTG
INTG
XLO
XLO
Q4 25
$233.2M
Q3 25
$237.8M
Q2 25
$240.5M
Q1 25
$241.5M
Q4 24
$227.2M
Q3 24
$218.1M
Q2 24
$225.7M
Q1 24
$225.0M
Stockholders' Equity
INTG
INTG
XLO
XLO
Q4 25
$-85.2M
$35.3M
Q3 25
$-86.7M
$-8.1M
Q2 25
$-86.1M
$7.1M
Q1 25
$-84.5M
$10.7M
Q4 24
$-83.9M
Q3 24
$-80.9M
Q2 24
$-80.3M
Q1 24
$-76.4M
Total Assets
INTG
INTG
XLO
XLO
Q4 25
$101.1M
$154.7M
Q3 25
$102.5M
$133.7M
Q2 25
$104.1M
$133.8M
Q1 25
$103.2M
$103.7M
Q4 24
$110.6M
Q3 24
$109.3M
Q2 24
$107.8M
Q1 24
$119.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INTG
INTG
XLO
XLO
Operating Cash FlowLast quarter
$-23.0K
$-2.0M
Free Cash FlowOCF − Capex
$-481.0K
$-2.1M
FCF MarginFCF / Revenue
-2.8%
-15.3%
Capex IntensityCapex / Revenue
2.6%
0.7%
Cash ConversionOCF / Net Profit
-0.02×
-0.19×
TTM Free Cash FlowTrailing 4 quarters
$739.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INTG
INTG
XLO
XLO
Q4 25
$-23.0K
$-2.0M
Q3 25
$-296.0K
$-17.5M
Q2 25
$5.9M
$-14.5M
Q1 25
$-854.0K
$29.0M
Q4 24
$-781.0K
Q3 24
$3.4M
Q2 24
$6.8M
Q1 24
$1.9M
Free Cash Flow
INTG
INTG
XLO
XLO
Q4 25
$-481.0K
$-2.1M
Q3 25
$-1.3M
Q2 25
$3.6M
$-14.9M
Q1 25
$-1.2M
$29.0M
Q4 24
$-1.1M
Q3 24
$3.1M
Q2 24
$2.7M
Q1 24
$1.1M
FCF Margin
INTG
INTG
XLO
XLO
Q4 25
-2.8%
-15.3%
Q3 25
-7.1%
Q2 25
22.5%
-184.0%
Q1 25
-6.8%
988.3%
Q4 24
-7.8%
Q3 24
18.3%
Q2 24
20.4%
Q1 24
7.6%
Capex Intensity
INTG
INTG
XLO
XLO
Q4 25
2.6%
0.7%
Q3 25
5.4%
0.0%
Q2 25
13.9%
5.0%
Q1 25
1.8%
0.8%
Q4 24
2.4%
Q3 24
1.6%
Q2 24
30.4%
Q1 24
4.9%
Cash Conversion
INTG
INTG
XLO
XLO
Q4 25
-0.02×
-0.19×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

INTG
INTG

Hotel Operations$12.7M73%
Real Estate Operation$4.6M27%

XLO
XLO

Segment breakdown not available.

Related Comparisons